Since March, the Ebola virus has killed at least 932 people in West Africa, the deadliest ever outbreak of the disease, and as the lethal hemorrhagic fever continues its spread, governments are taking drastic measures — from quarantining villages to closing schools — to stem the epidemic.
But perhaps there could have been another option to fight the virus. More than four years ago, a team of U.S. government scientists developed vaccine candidates that shielded monkeys from multiple strains of Ebola. Those vaccines, however, were never tested in human clinical trials — and not because the science wasn’t promising. One small trial on the monkeys, for example, had a 100 percent success rate of protecting the animals from the disease.
The factor preventing such trials in humans, though, has been cost, said Dr. Daniel Bausch, an associate professor of tropical medicine at the Tulane University School of Public Health who is currently stationed at the U.S. Naval Medical Research Unit 6 in Lima, Peru.
That’s because, while the National Institutes of Health and the U.S. government often fund the early animal safety and efficacy testing of a vaccine, pharmaceutical companies typically fund the human clinical trials to take a drug or vaccine to market.